独立董事签名: CHENG JUNPEI (程俊佩) 上海第一医药股份有限公司 2024 年第一次独立董事专门会议的审查意见 根据《中华人民共和国公司法》《中华人民共和国证券法》《上海证券交易所股票上 市规则》《上市公司独立董事管理办法》以及《公司章程》《独立董事专门会议工作细则》 等相关规定,上海第一医药股份有限公司于 2024年 1 月 3 日以通讯方式召开第十届董 事会 2024年第一次独立董事专门会议。本次会议推选了独立董事 CHENG JUNPEI（程俊 佩)担任独立董事专门会议召集人并主持会议,应出席独立董事 3人,实际出席独立董 事 3 人,会议的召集、召开和表决程序符合《公司章程》《独立董事专门会议工作细则》 等规定,所作审查意见合法有效。本次会议审议了如下事项并发表了同意的审查意见: 一、关于全资子公司向关联方租赁商铺暨关联交易的议案 上述关联交易系公司为满足经营发展和规划所需要,公司与关联方之间的交易遵循 了市场经济规律和市场公允原则,交易采用的原则是平等自愿、互惠互利,维护了交易 双方的利益,亦没有损害中小股东的利益,不会损害公司利益且公司独立性不会因此受 到影响。 因此,我们同意该事项 ...

证券代码：600833 证券简称：第一医药 公告编号：临 2024-001 重要内容提示：本次监事会不存在否决议案，没有监事投反对/弃权票。 上海第一医药股份有限公司第十届监事会第十次（临时）会议于 2023 年 12 月 31 日以邮件方式通知，于 2024 年 1 月 5 日以通讯方式召开。本次会议由监事长李峰召集 并主持，本次会议应参加表决监事 3 名，委托 0 名，实际参加表决监事 3 名。会议的召 开符合有关法律、行政法规、部门规章、规范性文件和公司章程的规定。根据会议议程， 本次会议审议通过了以下事项： 一、审议通过了《关于全资子公司向关联方租赁商铺暨关联交易的议案》 具体内容详见上海证券交易所网站 http://www.sse.com.cn 公司《关于全资子公 司向关联方租赁商铺暨关联交易的公告》（公告编号：临 2024-002）。 表决结果：赞成 3 名，反对 0 名，弃权 0 名 二、备查文件 公司第十届监事会第十次（临时）会议决议 特此公告。 上海第一医药股份有限公司 第十届监事会第十次（临时）会议决议公告 本公司监事会及全体监事保证本公告内容不存在任何虚假记载、误导 性陈述或者重大遗漏， ...

2023 年第三季度报告 证券代码：600833 证券简称：第一医药 上海第一医药股份有限公司 2023 年第三季度报告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真实、准确、完整， 不存在虚假记载、误导性陈述或重大遗漏，并承担个别和连带的法律责任。 公司负责人孙伟、主管会计工作负责人孙峥及会计机构负责人（会计主管人员）黄洁静保证 季度报告中财务信息的真实、准确、完整。 第三季度财务报表是否经审计 □是 √否 一、 主要财务数据 (一)主要会计数据和财务指标 单位：元 币种：人民币 | 项目 | 本报告期 | 本报告期比 | | 年初至报告 | | --- | --- | --- | --- | --- | | | | 上年同期增 | 年初至报告期末 | 期末比上年 | | | | 减变动幅度 | | 同期增减变 | | | | (%) | | 动幅度(%) | | 营业收入 | 437,563,712.09 | -47.38 | 1,335, ...

2023 年半年度报告 公司代码：600833 公司简称：第一医药 重要提示 上海第一医药股份有限公司 2023 年半年度报告 一、 本公司董事会、监事会及董事、监事、高级管理人员保证半年度报告内容的真实性、准确性、 完整性，不存在虚假记载、误导性陈述或重大遗漏，并承担个别和连带的法律责任。 二、 公司全体董事出席董事会会议。 三、 本半年度报告未经审计。 1 / 138 2023 年半年度报告 √适用 □不适用 本报告中所涉及的未来计划、发展战略等前瞻性陈述不构成公司对投资者的实质性承诺，请 投资者注意投资风险。 七、 是否存在被控股股东及其他关联方非经营性占用资金情况 否 八、 是否存在违反规定决策程序对外提供担保的情况？ 否 九、 是否存在半数以上董事无法保证公司所披露半年度报告的真实性、准确性和完整性 四、 公司负责人孙伟、主管会计工作负责人孙峥及会计机构负责人（会计主管人员）黄洁静声明： 保证半年度报告中财务报告的真实、准确、完整。 五、 董事会决议通过的本报告期利润分配预案或公积金转增股本预案 无 六、 前瞻性陈述的风险声明 | | 载有董事长亲笔签名的2023年半年度报告文本 | | --- | ...

2023 年第一季度报告 证券代码：600833 证券简称：第一医药 一、 主要财务数据 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示 公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真实、准确、完整，不存 在虚假记载、误导性陈述或重大遗漏，并承担个别和连带的法律责任。 上海第一医药股份有限公司 2023 年第一季度报告 公司负责人孙伟、主管会计工作负责人孙峥及会计机构负责人（会计主管人员）黄洁静保证季度 报告中财务信息的真实、准确、完整。 第一季度财务报表是否经审计 □是 √否 | 稀释每股收益（元/股） | | 0.1327 | | | 372.39 | | --- | --- | --- | --- | --- | --- | | 加权平均净资产收益率（%） | | 3.04 | 增加 | 2.26 | 个百分点 本报告期末比 | | | 本报告期末 | 上年度末 | | | 上年度末增减 变动幅度(%) | | 总资产 | 2,098,107,327.86 | 2,039,102,174. ...

Financial Performance - The company's operating revenue for 2022 reached ¥2,655,908,524.74, representing a year-on-year increase of 89.94%[23] - The net profit attributable to shareholders of the listed company was ¥143,556,293.25, a significant increase of 190.49% compared to the previous year[23] - The net cash flow from operating activities was ¥132,310,966.22, reflecting a year-on-year growth of 261.91%[23] - Basic earnings per share for 2022 were ¥0.64, up 190.91% from ¥0.22 in 2021[25] - The total assets of the company at the end of 2022 amounted to ¥2,039,102,174.03, an increase of 52.80% compared to the previous year[24] - The company reported a net profit of ¥139,891,611.56 after deducting non-recurring gains and losses, marking a 504.38% increase from the previous year[23] - Net profit attributable to shareholders increased by 190.49% year-on-year, primarily due to the increase in operating revenue[26] - Net profit attributable to shareholders after deducting non-recurring gains and losses increased by 504.38% year-on-year, mainly driven by the increase in operating revenue[26] - Net cash flow from operating activities increased by 261.91% year-on-year, mainly due to increased cash inflow from operating activities resulting from higher operating revenue[26] - Total assets grew by 52.80% year-on-year, primarily due to an increase in working capital matching sales[26] - Basic and diluted earnings per share increased by 190.91% year-on-year, reflecting the growth in net profit attributable to shareholders[26] - Basic earnings per share after deducting non-recurring gains and losses increased by 530.00% year-on-year, driven by the increase in net profit attributable to shareholders after adjustments[26] Dividends and Shareholder Returns - The company proposed a cash dividend of ¥1.95 per 10 shares, totaling ¥43,501,837.67, which accounts for 30.30% of the net profit attributable to shareholders[6] - The company’s total cash dividend amount for the year is 43,501,837.67 RMB, representing 30.30% of the consolidated net profit attributable to ordinary shareholders[167] - The cash dividend per share is set at 0.70 RMB (including tax), based on a total share capital of 223,086,347 shares[164] - The company must distribute at least 30% of the net profit attributable to shareholders as cash dividends if the annual profit is positive and undistributed profits are also positive[163] - The company has a cash dividend policy that emphasizes reasonable returns to investors, ensuring continuity and stability in profit distribution[156] Business Expansion and Operations - In 2022, the company launched a new store model called "Health Station," enhancing service capabilities and optimizing customer flow and sales data[35] - The company opened 30 new stores during the reporting period, including 26 direct-operated and 4 franchised stores, resulting in a 20% increase in the number of outlets in the Shanghai market compared to the end of 2021[36] - The company has rapidly developed cross-border business, collaborating with brand partners for online operations and establishing a "First Pharmacy Cross-Border Purchase" section in stores[35] - The company implemented a store partner system to improve the operational quality and efficiency of existing stores, with pilot stores showing optimization in gross profit and expenses[35] - The company has expanded its store network, including the renovation of the first pharmacy store and the introduction of new service areas such as health testing centers and traditional Chinese medicine clinics[46] - The company opened multiple new stores in Shanghai throughout 2022, with the last store opening in December, contributing to its market expansion strategy[71] Market Trends and Industry Insights - The national retail pharmacy market growth rates from 2018 to 2022 were 6.9%, 5.5%, 3.6%, 2.1%, and 10.2%, with a significant increase in 2022 due to a surge in demand for related drugs and medical devices[37] - The retail chain rate in China reached 57.22% by the end of 2021, an increase of 0.72% from 2020, and significantly up from 34.3% in 2011[38] - The B2C market for pharmaceuticals reached a scale of 25.4 billion yuan in the first half of 2022, with a market share of 12%, up from 5% in the same period of 2020[39] - The average price reduction for negotiated drugs in the new national medical insurance drug list was 61.71%, with a total of 2860 drug categories included[40] - The company ranked 39th in the sales total among reported pharmaceutical retail enterprises in 2021 and 53rd in the comprehensive competitiveness of pharmaceutical retail in 2022[44] Financial Management and Investments - The company reported a significant increase in accounts receivable by 78.20% to ¥237,999,101.33, due to increased sales[64] - The cash flow from financing activities improved by 205.54% to ¥249,148,497.79, reflecting an increase in short-term borrowings[62] - Inventory increased by 56.06% to ¥334,753,732.46, driven by stockpiling for new store openings and related materials[64] - The company reported a 112.25% increase in investment income to ¥4,121,455.93, due to higher dividends from investments[63] - The company has established a performance evaluation system linking management compensation to business performance, ensuring transparency in executive appointments[119] Risk Management and Governance - The company has outlined potential market and operational risks in its management discussion and analysis section[10] - The company is committed to enhancing its internal control and risk management systems to improve operational management and safeguard shareholder interests[121] - The company has compiled 89 internal control regulations to strengthen its governance framework, covering various aspects of business operations and risk management[121] - The company recognizes a talent shortage risk as competition for skilled professionals in the pharmaceutical sector intensifies, impacting future growth and operational efficiency[111] - The company faces risks from industry policy changes, including the impact of "two-invoice system," "GPO," and "volume-based procurement," which may increase cost pressures on pharmaceutical retail operations[109] Employee and Management Structure - The company has a total of 877 employees, with 279 in the parent company and 598 in major subsidiaries[150] - The company has a diverse employee composition, including 503 sales personnel and 151 technical staff[151] - The company has established a strategic committee to oversee long-term planning and market expansion initiatives[146] - The company has implemented a cash dividend policy that emphasizes reasonable returns to investors, ensuring continuity and stability in profit distribution[156] - The company has a training plan for 2022 that includes seven key initiatives aimed at enhancing employee skills and supporting business development[153] Future Outlook and Strategic Initiatives - The company provided guidance for 2023, expecting revenue growth of 12% to 15%, projecting total revenue between 11.2 billion RMB and 11.5 billion RMB[133] - The company plans to implement a new digital marketing strategy, aiming for a 25% increase in online sales by the end of 2023[139] - The company aims to expand its network coverage by filling gaps in underserved areas and increasing density in key regions, targeting a 15-minute service radius[106] - The company is exploring new business opportunities in cross-border health e-commerce to diversify its operations and create additional revenue streams[105] - The company plans to continue opening new retail stores while improving the quality and profitability of existing stores, optimizing procurement conditions to lower costs and enhance retail gross margins[107]

2022 年第三季度报告 第三季度财务报表是否经审计 □是 √否 一、 主要财务数据 证券代码：600833 证券简称：第一医药 上海第一医药股份有限公司 2022 年第三季度报告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真实、准确、完整， 不存在虚假记载、误导性陈述或重大遗漏，并承担个别和连带的法律责任。 公司负责人孙伟、主管会计工作负责人孙峥及会计机构负责人（会计主管人员）黄洁静保证 季度报告中财务信息的真实、准确、完整。 (一)主要会计数据和财务指标 单位：元 币种：人民币 | 项目 | 本报告期 | 本报告期 | 年初至报告期末 | 年初至报告 | | --- | --- | --- | --- | --- | | | | 比上年同 | | 期末比上年 | | | | 期增减变 | | 同期增减变 | | | | 动幅度(%) | | 动幅度(%) | | 营业收入 | 831,547,905.95 | 127.94 | 1,779, ...

2022 年半年度报告 二、 公司全体董事出席董事会会议。 三、 本半年度报告未经审计。 四、 公司负责人孙伟、主管会计工作负责人林华艳及会计机构负责人（会计主管人员）黄洁静声 明：保证半年度报告中财务报告的真实、准确、完整。 公司代码：600833 公司简称：第一医药 上海第一医药股份有限公司 2022 年半年度报告 1 / 132 2022 年半年度报告 重要提示 一、 本公司董事会、监事会及董事、监事、高级管理人员保证半年度报告内容的真实性、准确性、 完整性，不存在虚假记载、误导性陈述或重大遗漏，并承担个别和连带的法律责任。 本报告中所涉及的未来计划、发展战略等前瞻性陈述不构成公司对投资者的实质性承诺，请 投资者注意投资风险。 七、 是否存在被控股股东及其关联方非经营性占用资金情况 否 八、 是否存在违反规定决策程序对外提供担保的情况？ 否 九、 是否存在半数以上董事无法保证公司所披露半年度报告的真实性、准确性和完整性 否 十、 重大风险提示 五、 董事会决议通过的本报告期利润分配预案或公积金转增股本预案 无 六、 前瞻性陈述的风险声明 √适用 □不适用 公司已在本报告中详细描述存在的市场或业务经营风险 ...

重要内容提示 公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真实、准确、完整，不存 在虚假记载、误导性陈述或重大遗漏，并承担个别和连带的法律责任。 公司负责人孙伟、主管会计工作负责人林华艳及会计机构负责人（会计主管人员）黄洁静保证季 度报告中财务报表信息的真实、准确、完整。 2022 年第一季度报告 证券代码：600833 证券简称：第一医药 上海第一医药股份有限公司 2022 年第一季度报告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 第一季度财务报表是否经审计 □是 √否 一、 主要财务数据 (一)主要会计数据和财务指标 单位：元 币种：人民币 | 项目 | 本报告期 | 本报告期比上年同期增减 | | --- | --- | --- | | | | 变动幅度(%) | | 营业收入 | 391,426,974.40 | 18.46 | | 归属于上市公司股东的净利润 | 6,258,328.50 | -37.74 | | 归属于上市公司股东的扣除非经常 | 6,114,320.13 | -37. ...

2021 年年度报告 四、 公司负责人孙伟、主管会计工作负责人林华艳及会计机构负责人（会计主管人员）黄洁静 声明：保证年度报告中财务报告的真实、准确、完整。 公司代码：600833 公司简称：第一医药 五、 董事会决议通过的本报告期利润分配预案或公积金转增股本预案 上海第一医药股份有限公司 2021 年年度报告 1 / 175 2021 年年度报告 重要提示 一、 本公司董事会、监事会及董事、监事、高级管理人员保证年度报告内容的真实性、准确性、 完整性，不存在虚假记载、误导性陈述或重大遗漏，并承担个别和连带的法律责任。 二、 公司全体董事出席董事会会议。 三、 立信会计师事务所（特殊普通合伙）为本公司出具了标准无保留意见的审计报告。 2 / 175 2021 年年度报告 根据立信会计师事务所（特殊普通合伙）出具的标准无保留意见的审计报告，公司2021年度 归属于上市公司股东的净利润49,419,058.45元，母公司实现净利润74,721,242.52元。根据《公 司法》和《章程》规定提取10%法定盈余公积7,472,124.25元，当年实现可供分配利润为 67,249,118.27 元 ， 加 上 年 初 ...